Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The Net income (loss) per share - attributable to PAVmed Inc. - basic and diluted and Net income (loss) per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Numerator
Net income (loss) - before noncontrolling interest	$	60,711		$	(21,750	)	$	27,285		$	(61,855	)
Net income (loss) attributable to noncontrolling interest		3,688			4,079			11,075			11,716
Net income (loss) - as reported, attributable to PAVmed Inc.	$	64,399		$	(17,671	)	$	38,360		$	(50,139	)
Series B Convertible Preferred Stock dividends – earned	$	(83	)	$	(77	)	$	(244	)	$	(226	)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests	$	—		$	—		$	(7,496	)	$	—
Net income (loss) attributable to PAVmed Inc. common stockholders used in basic EPS calculation	$	64,316		$	(17,748	)	$	30,620		$	(50,365	)
Fair Value Adjustment for diluted EPS calculation	$	(240	)	$	—		$	3,378		$	—
Net income (loss) attributable to PAVmed Inc. common stockholders used in dilutive EPS calculation	$	64,076		$	(17,748	)	$	33,998		$	(50,365	)
Denominator
Weighted average common shares outstanding, basic		10,005,379			7,462,751			9,286,999			6,967,764
Weighted average common shares outstanding, diluted		44,475,638			7,462,751			43,069,449			6,967,764
Net income (loss) per share (1)
Net income (loss) per share attributable to PAVmed Inc. common stockholders, basic	$	6.43		$	(2.38	)	$	3.30		$	(7.23	)
Net income (loss) per share attributable to PAVmed Inc. common stockholders, diluted	$	1.44		$	(2.38	)	$	0.79		$	(7.23	)

(1) - Convertible preferred stock and restricted stock awards would potentially be considered a participating security under the two-class method of calculating net income (loss) per share. For periods where losses are presented, such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net income (loss) per share calculation for the periods indicated.

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	September 30,
	2024		2023
Stock options		1,233,107		1,138,632
Restricted stock awards		—		70,528
Series Z Warrants		795,830		795,830
Series B Convertible Preferred Stock		—		85,307
Total		2,028,937		2,090,297